Hsbc Holdings PLC Sells 19,530 Shares of CVS Health Corporation $CVS

Hsbc Holdings PLC lowered its holdings in CVS Health Corporation (NYSE:CVS) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,269,801 shares of the pharmacy operator’s stock after selling 19,530 shares during the period. Hsbc Holdings PLC’s holdings in CVS Health were worth $180,203,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Swiss RE Ltd. acquired a new stake in shares of CVS Health in the fourth quarter valued at about $26,000. Sankala Group LLC acquired a new position in CVS Health during the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd grew its stake in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares in the last quarter. Mcguire Capital Advisors Inc. acquired a new position in shares of CVS Health during the 4th quarter worth approximately $28,000. Finally, Ares Financial Consulting LLC bought a new stake in shares of CVS Health during the 4th quarter worth approximately $29,000. 80.66% of the stock is owned by institutional investors.

CVS Health Trading Down 0.1%

CVS stock opened at $98.26 on Friday. CVS Health Corporation has a one year low of $58.50 and a one year high of $102.77. The stock has a market cap of $125.38 billion, a price-to-earnings ratio of 43.29, a price-to-earnings-growth ratio of 0.96 and a beta of 0.62. The company has a fifty day moving average price of $89.31 and a two-hundred day moving average price of $81.48. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter last year, the company posted $2.25 EPS. CVS Health’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current year.

Insider Buying and Selling

In related news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

CVS has been the subject of several recent analyst reports. Royal Bank Of Canada increased their price objective on CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Mizuho upped their price target on shares of CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Leerink Partners reiterated an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. Truist Financial lifted their price objective on shares of CVS Health from $102.00 to $108.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Finally, DA Davidson upped their target price on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $100.68.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.